Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy
Brief Summary: The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.


Options:
A: Arm Label: Lanreotide Autogel (Somatuline Depot) 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide | Arm Label: Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanreotide; Assigned to Arm(s): Lanreotide Autogel (Somatuline Depot) 120 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE
B: Arm Label: Arm I (octreotide acetate and bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate | Arm Label: Arm II (octreotide acetate and recombinant interferon alfa-2b); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate, Biological: Recombinant Interferon Alfa-2b | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: DRUG; Name: Octreotide Acetate; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: BIOLOGICAL; Name: Recombinant Interferon Alfa-2b; Assigned to Arm(s): Arm II (octreotide acetate and recombinant interferon alfa-2b)
C: Arm Label: 250 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: 500 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-matching telotristat etiprate | Arm Label: Telotristat Etiprate Open-Label Extension; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Intervention Type: DRUG; Name: Telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Telotristat Etiprate Open-Label Extension | Intervention Type: DRUG; Name: Placebo-matching telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Placebo, Telotristat Etiprate Open-Label Extension
D: Arm Label: lanreotide (Autogel formulation); Type: EXPERIMENTAL; Interventions: Drug: lanreotide (Autogel formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide (Autogel formulation); Assigned to Arm(s): lanreotide (Autogel formulation) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C